Noninvasive Targeted Transcranial Neuromodulation via Focused Ultrasound Gated Drug Release from Nanoemulsions.
Noninvasive Targeted Transcranial Neuromodulation via Focused Ultrasound Gated Drug Release from Nanoemulsions.
复制标题
DOI：
10.1021/acs.nanolett.6b03517
复制
发表时间：
2017-02-08
期刊：
影响因子：
10.8
通讯作者：
Green JJ
中科院分区：
文献类型：
--
作者：
Airan RD;Meyer RA;Ellens NP;Rhodes KR;Farahani K;Pomper MG;Kadam SD;Green JJ
对清醒受试者的大脑进行有针对性的非侵入性神经调节可能会彻底改变基础和临床神经科学。为了实现这一目标，我们已经开发出纳米颗粒，允许非侵入性的神经调节药物，在这种情况下，小分子麻醉剂异丙酚，在应用聚焦超声。这些纳米颗粒由生物可降解和生物相容性成分组成，并使用当前临床经颅聚焦超声系统容易实现的超声处理参数进行激活。这些颗粒足够有效，它们的激活可以在急性大鼠癫痫发作模型中沉默癫痫发作。值得注意的是，没有证据表明使用它们会造成脑实质损伤或血脑屏障开放。这些颗粒的进一步发展有望沿着各种药理学轴进行无创、局部和图像引导的临床神经调节。
Targeted, noninvasive neuromodulation of the brain of an otherwise awake subject could revolutionize both basic and clinical neuroscience. Toward this goal, we have developed nanoparticles that allow noninvasive uncaging of a neuromodulatory drug, in this case the small molecule anesthetic propofol, upon the application of focused ultrasound. These nanoparticles are composed of biodegradable and biocompatible constituents and are activated using sonication parameters that are readily achievable by current clinical transcranial focused ultrasound systems. These particles are potent enough that their activation can silence seizures in an acute rat seizure model. Notably, there is no evidence of brain parenchymal damage or blood-brain barrier opening with their use. Further development of these particles promises noninvasive, focal, and image-guided clinical neuromodulation along a variety of pharmacological axes.